

Baxter receives CE Mark approval for dialysis system

04 April 2015 | News | By BioSpectrum Bureau

Baxter receives CE Mark approval for dialysis system



Baxter has announced the completion of CE marking (market approval) in Europe for HOMECHOICE CLARIA, an automated peritoneal dialysis (APD) system integrated with the SHARESOURCE web-based connectivity platform.

The APD system is designed with user-friendly features and secure two-way connectivity so healthcare providers can have increased visibility to monitor their patients' home peritoneal dialysis (PD) treatments and adjust prescriptions as necessary. PD is a therapy option performed primarily at home by end-stage renal disease patients.

"CLARIA builds upon our market-leading HOMECHOICE APD device with new features to make the system more intuitive for patients to operate in their home and while traveling," said Dr Bruce Culleton, vice-president, renal therapeutic area lead, Baxter. He added, "Additionally, SHARESOURCE, the system's web-based platform, provides physicians remote access to their home patients' treatment information allowing for more timely and personalized care."

HOMECHOICE CLARIA with SHARESOURCE is also designed to save clinics time and improve healthcare practice efficiencies by reducing manual input of data and gathering both patient and clinic data into organized patient report dashboards that are easily accessed and viewed by healthcare providers. In addition, the HOMECHOICE CLARIA system features a large, two-line display screen for better visibility, and a universal interface that is available in 41 languages.

Baxter plans to initiate the commercial launch of HOMECHOICE CLARIA with SHARESOURCE in select European and

Asian countries in the first half of 2015.

"Every patient with end-stage renal disease deserves access to individualized care. HOMECHOICE CLARIA with SHARESOURCE represents Baxter's continued commitment to advancing renal technology that offers healthcare providers and patients therapy options for end-stage renal disease," said Mr Jill Schaaf, president of Baxter's Renal business.